Successful Completion of Phase I Study for Lead Asset EP395

EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human study with EP395 in healthy subjects.